Q1 2025 Management View CEO Eric Lefkofsky highlighted a record quarter for Tempus, with quarterly revenue increasing 75.4% ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery. The companies say the ...

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point ...

Despite a turbulent 2025, Ark Invest CEO Cathie Wood is currently sitting on a big win with her investment in Tempus AI ...

The AstraZeneca deal is also significant for the long-term outlook. Tempus already reported interest from other pharmaceutical giants and may announce additional deals soon. Before you make your ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

Tempus AI saw its share prices increase by 12.59 ... announcement to build the largest foundation model in oncology with AstraZeneca and Pathos,” he added. Overall, TEM ranks 5th on our list ...

Nancy Pelosi's newest stock bet, Tempus AI, remains an enticing buy following a promising Q1 2025 earnings report.

Tempus AI delivered a record quarter, supported by strong revenue growth across its segments and a landmark $200 million agreement with AstraZeneca and Pathos. The company raised its full-year ...